Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Almost 300 million people globally have chronic hepatitis B
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Both the India and GCC entities will be operated by separate dedicated management teams
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Subscribe To Our Newsletter & Stay Updated